INOZYME PHARMA INC's ticker is INZY and the CUSIP is 45790W108. A total of 40 filers reported holding INOZYME PHARMA INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $921,169 | -24.6% | 219,326 | 0.0% | 0.21% | -26.2% |
| Q2 2023 | $1,221,646 | -2.8% | 219,326 | 0.0% | 0.29% | -11.9% |
| Q1 2023 | $1,256,738 | +445.7% | 219,326 | 0.0% | 0.33% | +391.0% |
| Q4 2022 | $230,292 | +23.8% | 219,326 | +216.4% | 0.07% | +26.4% |
| Q3 2022 | $186,000 | -43.8% | 69,326 | 0.0% | 0.05% | -44.8% |
| Q2 2022 | $331,000 | +386.8% | 69,326 | +314.5% | 0.10% | +540.0% |
| Q1 2022 | $68,000 | -40.4% | 16,726 | 0.0% | 0.02% | -34.8% |
| Q4 2021 | $114,000 | -41.2% | 16,726 | 0.0% | 0.02% | -45.2% |
| Q3 2021 | $194,000 | -31.9% | 16,726 | 0.0% | 0.04% | -30.0% |
| Q2 2021 | $285,000 | -13.9% | 16,726 | 0.0% | 0.06% | -18.9% |
| Q1 2021 | $331,000 | -4.1% | 16,726 | 0.0% | 0.07% | -11.9% |
| Q4 2020 | $345,000 | -21.6% | 16,726 | 0.0% | 0.08% | -17.6% |
| Q3 2020 | $440,000 | – | 16,726 | – | 0.10% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Pivotal bioVenture Partners Investment Advisor LLC | 4,494,851 | $18,878,374 | 7.53% |
| CHI Advisors LLC | 1,270,027 | $5,334,112 | 2.11% |
| Samsara BioCapital, LLC | 1,562,500 | $6,562,500 | 2.01% |
| Affinity Asset Advisors, LLC | 1,379,852 | $5,795,378 | 1.63% |
| Sofinnova Investments, Inc. | 4,280,308 | $17,977,294 | 1.13% |
| SPHERA FUNDS MANAGEMENT LTD. | 1,234,907 | $5,186,609 | 0.94% |
| Octagon Capital Advisors LP | 1,300,000 | $5,460,000 | 0.84% |
| NEA Management Company, LLC | 2,437,689 | $10,238,294 | 0.79% |
| Knott David M Jr | 454,008 | $1,907 | 0.73% |
| Rock Springs Capital Management LP | 3,681,174 | $15,460,931 | 0.41% |